GovWhitePapers Logo

Sorry, your browser is not compatible with this application. Please use the latest version of Google Chrome, Mozilla Firefox, Microsoft Edge or Safari.

“Big Pharma” Is a Normal Industry

Despite growing calls from across the political spectrum to impose price controls on prescription drugs, this report argues that many common criticisms of the pharmaceutical industry don’t align with the data. U.S. drug companies, while often portrayed as excessively profitable, actually invest more heavily in research and development than nearly any other industry. The analysis shows that Americans enjoy faster access to new medications compared to other countries, largely due to a private-sector-driven innovation system. Curbing prices too aggressively, the report warns, could stall future drug development and erode global biopharmaceutical leadership.

“Big Pharma” Is a Normal Industry
Format:
  • White Paper
Topics:
Website:Visit Publisher Website
Author(s):
  • Robert D. Atkinson
Publisher:Information Technology & Innovation Foundation
Published:May 1, 2025
License:Copyrighted
Copyright:© 2025 Information Technology and Innovation Foundation (ITIF). All rights reserved.
Tags:innovation systempharma investmentpharmaceutical r&d
  • Share:
  • Share on Facebook
  • Share on X
  • Share via Email
  • Share on LinkedIn

Contact Publisher

Claim Content

Stay Ahead of
Government Tech Trends

Get exclusive access to the latest white papers, executive orders, and tech updates delivered to your inbox.